Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8895283 | 1.00 | PTGS2 (0.42) | PTGS2PTGS1SIRT1ALOX5CYP1A2 | |
| SCHEMBL8895650 | 0.84 | PTGS2 (0.49) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8933401 | 0.84 | PTGS2 (0.49) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8894180 | 0.84 | PTGS2 (0.45) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8933499 | 0.84 | PTGS2 (0.45) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL2746044 | 0.81 | PTGS2 (0.52) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL2746042 | 0.81 | PTGS2 (0.52) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8532127 | 0.81 | PTGS2 (0.46) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8532129 | 0.81 | PTGS2 (0.46) | PTGS2PTGS1ALOX5CYP1A2CYP2C9 | |
| SCHEMBL8583053 | 0.78 | SIRT1 (0.39) | PTGS2PTGS1SIRT1ALOX5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0722729-A2 | Aryl-substituted rhodanines for treating multiple sclerosis | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0391644-B1 | Aryl-substituted rhodanine derivatives | LILLY CO ELI (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5356917-A | Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals | ELI LILLY AND COMPANY (US) | 1994-10-18 | — | — | US | disclosed |
| US-5158966-A | Aryl-substituted rhodanine derivatives | THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-10-27 | — | — | US | disclosed |
| EP-0500337-A1 | Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes | UNIVERSITY OF COLORADO FOUNDATION, INC. (US) | 1992-08-26 | — | — | EP | disclosed |